Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lipegfilgrastim

- PMLiVE

Lonza ends biosimilars deal with Teva

Chemical firm cuts losses after four-year development deal

- PMLiVE

Setback for Teva as court dismisses Copaxone lawsuit

District Court dismisses claim that Mylan breached Teva’s patents on MS drug

Teva and Sun pay dearly for ‘at-risk’ generic Protonix launch

Will pay $2.15bn in landmark patent infringement lawsuit

- PMLiVE

France investigates Teva after packaging mix-up

Some packages of diuretic furosemide found to contain sleeping pill zopiclone

- PMLiVE

Teva appoints chief strategy officer

Paul Sekhri has experience at Novartis, Ariad and TPG Biotech

- PMLiVE

Leukaemia drug prices “unsustainable” say cancer experts

Study says patients may not be able to afford effective treatment

- PMLiVE

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

Teva facing $2bn liability for at-risk generic Protonix launch

Potential litigation costs from Pfizer are triple the generics firm's original estimates

- PMLiVE

Teva wins challenge to BMS’ Baraclude patent in US

US court says hepatitis B treatment’s patent is invalid

- PMLiVE

Teva suffers setback as Nuvigil fails late-stage trial

Disappointing results in treating bipolar disorder but drug development continues

- PMLiVE

Teva expands presence in South Korea with Handok deal

Will supply products for distribution in market worth $14bn

- PMLiVE

Teva plans revamp as 2013 revenues expected to fall short

Expects increased competition for biggest-selling drug Copaxone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links